8-K: PowerUp Acquisition Corp. Amends Merger Agreement with Aspire Biopharma, Adjusts Consideration and Equity Plan

PowerUp Acquisition Corp. and Aspire Biopharma have amended their merger agreement, adjusting the merger consideration, equity incentive plan size, and extending the due diligence period.

Summary

• PowerUp Acquisition Corp. has amended its merger agreement with Aspire Biopharma.
• The amendment adjusts the merger consideration to align with the anticipated post-closing ownership percentage of Aspire stockholders.
• The size of the equity incentive plan for the initial fiscal year following the closing has also been adjusted to match the parties' expectations.
• The amendment provides additional time for the parties to deliver disclosure schedules and conduct due diligence reviews.
• The merger consideration is now defined as $350 million, less any shortfall in Aspire's cash at closing compared to a minimum cash condition (if waived), and less any company indebtedness at closing.
• The equity incentive plan will reserve shares equal to the greater of 10% of the post-closing outstanding shares or 5,000,000 shares, with an evergreen provision for annual increases.
• The deadline for delivering disclosure schedules is now September 18, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the amendment indicates a need for adjustments, it also shows a commitment to completing the merger with terms that are more aligned with the parties' expectations. The risks are clearly outlined, which is a positive for transparency.

Positives

• The adjustments to the merger consideration and equity incentive plan size align with the parties' original intentions.
• The extension of the due diligence period allows for a more thorough review of the transaction.
• The evergreen provision in the equity incentive plan ensures continued alignment of incentives.

Negatives

• The need for adjustments to the merger agreement suggests potential discrepancies in the initial understanding of the deal.
• The extended due diligence period could indicate complexities or issues that require further investigation.

Risks

• The merger may not be completed in a timely manner or at all.
• The failure to satisfy closing conditions could terminate the agreement.
• Redemptions by PowerUp's public shareholders could exceed anticipated levels.
• Aspire may not be able to execute its growth strategies.
• There are risks related to supply chain disruptions and the ability to maintain effective internal controls.
• Aspire may need to raise additional capital, which may not be available on acceptable terms.
• There are risks associated with intellectual property protection and potential product liability lawsuits.

Future Outlook

The document includes forward-looking statements regarding the anticipated benefits and timing of the proposed business combination, as well as the future financial condition and performance of the combined company. However, these statements are subject to various risks and uncertainties, and actual results may differ materially.

Management Comments

• The parties acknowledge and agree that the amount of Merger Consideration set forth in the Merger Agreement is inconsistent with the aggregate post-Closing ownership percentage of the Company Stockholders that the Parties had anticipated as part of the consummation of the Transaction.
• The parties believe it is in their collective best interests to adjust the amount of Merger Consideration to be consistent with the aggregate post-Closing ownership percentage of the Company Stockholders that the Parties had anticipated as part of the consummation of the Transaction.

Industry Context

This announcement reflects a common practice in SPAC mergers where adjustments to the initial agreement are made during the due diligence process. The focus on aligning ownership percentages and equity incentives is typical in such transactions.

Comparison to Industry Standards

• The adjustment of merger consideration and equity incentive plans is a common practice in SPAC transactions, reflecting the dynamic nature of due diligence and negotiations.
• The use of an evergreen provision in the equity incentive plan is a standard mechanism to ensure long-term alignment of interests between management and shareholders.
• The timeline for disclosure schedules and due diligence is consistent with industry norms for complex merger agreements.

Stakeholder Impact

• Shareholders of PowerUp will be impacted by the merger and the potential for redemptions.
• Aspire's employees and business relationships may be affected by the merger.
• The combined company's future performance will impact all stakeholders.

Next Steps

• The parties will deliver final-form disclosure schedules by September 18, 2024.
• The parties will review the disclosure schedules and address any material issues.
• PowerUp will file a registration statement with the SEC, including a proxy statement/prospectus.
• PowerUp shareholders will vote on the proposed business combination.

Key Dates

Keywords

merger, acquisition, biopharma, amendment, equity incentive plan, due diligence, merger consideration, business combination, disclosure schedules